#ipsc rpe

[pknoepfl]

Good stem cell news as Takahashi IPS Cell Trial to Resume

Good stem cell news as Takahashi IPS Cell Trial to Resume

Some good news today as the pioneering induced pluripotent stem (IPS) cell trial led by Dr. Masayo Takahashi will resume.

This clinical study with a focus on macular degeneration has been on hold for quite some time due to regulatory changes in Japan. There had also been concerns over mutations in the 2nd patient’s IPS cell product.

As previous signs had indicated, the new clinical work will have…

View On WordPress

[pknoepfl]

New Paper on IPS Cell Immunogenicity, Clinical Insights, & Possible Solutions

New Paper on IPS Cell Immunogenicity, Clinical Insights, & Possible Solutions

Can cells produced from autologous induced pluripotent stem cells (IPSC or IPS cells) sometimes be immunogenic in patients?

This key question has remained somewhat unsettled due to varied findings over the years (e.g. see here), but many of us had generally felt in the last couple years that immunogenicity in an autologous context wouldn’t be a major problem.

This is a big deal because if human…

View On WordPress

[pknoepfl]

Landmark IPSC clinical study on hold due to genomic issue

Landmark IPSC clinical study on hold due to genomic issue

The pioneering induced pluripotent stem cell (IPSC) clinical study in Japan led by pioneering stem cell clinical researcher Dr. Masayo Takahashi has been stopped reports the WSJ in Japan. This development is confirmed by other sources and in a PDF report by RIKEN (in Japanese here).

One patient was transplanted in September 2014 with their own IPSC-derived retinal pigment epithelial cells (using…

View On WordPress